166 related articles for article (PubMed ID: 21948300)
1. Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation.
Rettinger E; Willasch AM; Kreyenberg H; Borkhardt A; Holter W; Kremens B; Strahm B; Woessmann W; Mauz-Koerholz C; Gruhn B; Burdach S; Albert MH; Schlegel PG; Klingebiel T; Bader P
Blood; 2011 Nov; 118(20):5681-8. PubMed ID: 21948300
[TBL] [Abstract][Full Text] [Related]
2. Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective.
Bader P; Kreyenberg H; Hoelle W; Dueckers G; Kremens B; Dilloo D; Sykora KW; Niemeyer C; Reinhardt D; Vormoor J; Gruhn B; Lang P; Greil J; Handgretinger R; Niethammer D; Klingebiel T; Beck JF
Bone Marrow Transplant; 2004 Apr; 33(8):815-21. PubMed ID: 14990984
[TBL] [Abstract][Full Text] [Related]
3. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children.
Bader P; Klingebiel T; Schaudt A; Theurer-Mainka U; Handgretinger R; Lang P; Niethammer D; Beck JF
Leukemia; 1999 Dec; 13(12):2079-86. PubMed ID: 10602432
[TBL] [Abstract][Full Text] [Related]
4. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
[TBL] [Abstract][Full Text] [Related]
5. [Relapse of childhood ALL, AML and MDS after allogeneic stem cell transplantation can be prevented by donor lymphocyte infusion in a critical stage of increasing mixed chimerism].
Beck JF; Klingebiel T; Kreyenberg H; Schaudt A; Wölle W; Niethammer D; Bader P
Klin Padiatr; 2002; 214(4):201-5. PubMed ID: 12165902
[TBL] [Abstract][Full Text] [Related]
6. Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Lee HC; Saliba RM; Rondon G; Chen J; Charafeddine Y; Medeiros LJ; Alatrash G; Andersson BS; Popat U; Kebriaei P; Ciurea S; Oran B; Shpall E; Champlin R
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1948-54. PubMed ID: 26183077
[TBL] [Abstract][Full Text] [Related]
7. Early mixed chimerism-based preemptive immunotherapy in children undergoing allogeneic hematopoietic stem cell transplantation for acute leukemia.
Horn B; Wahlstrom JT; Melton A; Liou A; Ouachee-Chardin M; Sunkersett G; Willert J; Hwang J; Expose-Spencer J; Cowan MC; Facchino J; Dvorak CC
Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28205327
[TBL] [Abstract][Full Text] [Related]
8. Preemptive Interferon-α Therapy Could Protect Against Relapse and Improve Survival of Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Results of Two Registry Studies.
Shen MZ; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Zhao XS; Qin YZ; Chang YJ; Liu KY; Huang XJ; Mo XD
Front Immunol; 2022; 13():757002. PubMed ID: 35154096
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
11. Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia.
Barrios M; Jiménez-Velasco A; Román-Gómez J; Madrigal ME; Castillejo JA; Torres A; Heiniger A
Haematologica; 2003 Jul; 88(7):801-10. PubMed ID: 12857560
[TBL] [Abstract][Full Text] [Related]
12. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?
Bader P; Kreyenberg H; Hoelle W; Dueckers G; Handgretinger R; Lang P; Kremens B; Dilloo D; Sykora KW; Schrappe M; Niemeyer C; Von Stackelberg A; Gruhn B; Henze G; Greil J; Niethammer D; Dietz K; Beck JF; Klingebiel T
J Clin Oncol; 2004 May; 22(9):1696-705. PubMed ID: 15117992
[TBL] [Abstract][Full Text] [Related]
13. Effects of chimerism on graft-versus-host disease, disease recurrence, and survival after HLA-identical marrow transplantation in Iran.
Alimoghaddam K; Ghaffari H; Foroughi F; Chardouli B; Sanaat Z; Bahar B; Mousavi A; Iravani M; Ghavamzadeh A
Arch Iran Med; 2006 Apr; 9(2):99-103. PubMed ID: 16649348
[TBL] [Abstract][Full Text] [Related]
14. Peripheral blood late mixed chimerism in leucocyte subpopulations following allogeneic stem cell transplantation for childhood malignancies: does it matter?
Pichler H; Fritsch G; König M; Daxberger H; Glogova E; Pötschger U; Breuer S; Lawitschka A; Güclü ED; Karlhuber S; Holter W; Haas OA; Lion T; Matthes-Martin S
Br J Haematol; 2016 Jun; 173(6):905-17. PubMed ID: 26996395
[TBL] [Abstract][Full Text] [Related]
15. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
[TBL] [Abstract][Full Text] [Related]
16. Impact of Day 14 Peripheral Blood Chimerism after Allogeneic Hematopoietic Stem Cell Bone Transplantation on the Treatment Outcome of Non-Malignant Disease.
Choi YB; Lee JW; Sung KW; Koo HH; Kim HJ; Yoo KH
J Korean Med Sci; 2019 Feb; 34(6):e46. PubMed ID: 30787679
[TBL] [Abstract][Full Text] [Related]
17. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT.
Bader P; Beck J; Frey A; Schlegel PG; Hebarth H; Handgretinger R; Einsele H; Niemeyer C; Benda N; Faul C; Kanz L; Niethammer D; Klingebiel T
Bone Marrow Transplant; 1998 Mar; 21(5):487-95. PubMed ID: 9535041
[TBL] [Abstract][Full Text] [Related]
18. Chimerism-based pre-emptive immunotherapy with fast withdrawal of immunosuppression and donor lymphocyte infusions after allogeneic stem cell transplantation for pediatric hematologic malignancies.
Horn B; Petrovic A; Wahlstrom J; Dvorak CC; Kong D; Hwang J; Expose-Spencer J; Gates M; Cowan MJ
Biol Blood Marrow Transplant; 2015 Apr; 21(4):729-37. PubMed ID: 25644958
[TBL] [Abstract][Full Text] [Related]
19. A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen.
Satwani P; Bhatia M; Garvin JH; George D; Dela Cruz F; Le Gall J; Jin Z; Schwartz J; Duffy D; van de Ven C; Foley S; Hawks R; Morris E; Baxter-Lowe LA; Cairo MS
Biol Blood Marrow Transplant; 2012 Feb; 18(2):324-9. PubMed ID: 22079471
[TBL] [Abstract][Full Text] [Related]
20. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]